Sequencing Treatment for Castration-Resistant Prostate Cancer (Q39002328)

8 September 2017

1 reference

title

Sequencing Treatment for Castration-Resistant Prostate Cancer (English)

1 reference

8 September 2017

1 reference

Emmanuel S. Antonarakis

series ordinal

2

object named as

Emmanuel S Antonarakis

1 reference

8 September 2017

Catherine E Handy

1

1 reference

8 September 2017

publication date

1 December 2016

1 reference

Current Treatment Options in Oncology

8 September 2017

published in

1 reference

8 September 2017

volume

17

1 reference

8 September 2017

issue

12

1 reference

8 September 2017

page(s)

64

1 reference

Trends in prostate cancer in the United States

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Enzalutamide in metastatic prostate cancer before chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Alpha emitter radium-223 and survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

DNA Repair in Prostate Cancer: Biology and Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0438-9

Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola

21 January 2018

1 reference

12 December 2020

Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis

1 reference

12 December 2020

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer

1 reference

12 December 2020

1 reference

12 December 2020

Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer

1 reference

12 December 2020

10.1007/S11864-016-0438-9

Identifiers

DOI

1 reference

8 September 2017

1 reference